Who
James Mulay
Director
Company insider
Files Form 4 as: Director, CG Oncology; Director, Fulgent Genetics.
In numbers
- Trades disclosed
- 74
- Buys
- 0
- Sells
- 10
- Bought
- $0
- Sold
- $10.1M
- Companies
- 2
- Companies where not an officer
- 2
- First trade
- 26 Oct 2016
- Last trade
- 10 Jul 2026
- Last filed
- 14 Jul 2026
Companies traded
Activity over time
1 Sep 2025 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 10 Jul 2026filed 14 Jul 2026 | CGON CG OncologyBiotechnology | SEC FORM 4 Code M | $644K24,165 at $26.63 | filing |
| 10 Jul 2026filed 14 Jul 2026 | CGON CG OncologyBiotechnology | SEC FORM 4 Sold | $1.8M24,165 at $75.16 | filing |
| 10 Jul 2026filed 14 Jul 2026 | CGON CG Oncologyoption or derivative · Biotechnology | SEC FORM 4 Code M | —24,165 at $0.00 | filing |
| 10 Jul 2026filed 14 Jul 2026 | CGON CG Oncologyoption or derivative · Biotechnology | SEC FORM 4 Code M | —24,165 at $0.00 | filing |
| 10 Jul 2026filed 14 Jul 2026 | CGON CG OncologyBiotechnology | SEC FORM 4 Code M | $644K24,165 at $26.63 | filing |
| 10 Jul 2026filed 14 Jul 2026 | CGON CG OncologyBiotechnology | SEC FORM 4 Sold | $1.8M24,165 at $75.16 | filing |
| 15 Jun 2026filed 16 Jun 2026 | CGON CG OncologyBiotechnology | SEC FORM 4 Code M | $2,433654 at $3.72 | filing |
| 15 Jun 2026filed 16 Jun 2026 | CGON CG OncologyBiotechnology | SEC FORM 4 Sold | $39K654 at $60.12 | filing |
| 15 Jun 2026filed 16 Jun 2026 | CGON CG OncologyBiotechnology | SEC FORM 4 Code M | $16K1,310 at $12.59 | filing |
| 15 Jun 2026filed 16 Jun 2026 | CGON CG Oncologyoption or derivative · Biotechnology | SEC FORM 4 Code M | —654 at $0.00 | filing |
| 15 Jun 2026filed 16 Jun 2026 | CGON CG Oncologyoption or derivative · Biotechnology | SEC FORM 4 Code M | —1,310 at $0.00 | filing |
| 15 Jun 2026filed 16 Jun 2026 | CGON CG OncologyBiotechnology | SEC FORM 4 Sold | $79K1,310 at $60.12 | filing |
| 15 Jun 2026filed 16 Jun 2026 | CGON CG Oncologyoption or derivative · Biotechnology | SEC FORM 4 Code M | —654 at $0.00 | filing |
| 15 Jun 2026filed 16 Jun 2026 | CGON CG Oncologyoption or derivative · Biotechnology | SEC FORM 4 Code M | —1,310 at $0.00 | filing |
| 15 Jun 2026filed 16 Jun 2026 | CGON CG OncologyBiotechnology | SEC FORM 4 Code M | $2,433654 at $3.72 | filing |
| 15 Jun 2026filed 16 Jun 2026 | CGON CG OncologyBiotechnology | SEC FORM 4 Sold | $39K654 at $60.12 | filing |
| 15 Jun 2026filed 16 Jun 2026 | CGON CG OncologyBiotechnology | SEC FORM 4 Code M | $16K1,310 at $12.59 | filing |
| 15 Jun 2026filed 16 Jun 2026 | CGON CG OncologyBiotechnology | SEC FORM 4 Sold | $79K1,310 at $60.12 | filing |
| 4 Jun 2026filed 5 Jun 2026 | CGON CG Oncologyoption or derivative · Biotechnology | SEC FORM 4 Code A | —9,354 at $0.00 | filing |
| 4 Jun 2026filed 5 Jun 2026 | CGON CG Oncologyoption or derivative · Biotechnology | SEC FORM 4 Code A | —9,354 at $0.00 | filing |
News
CG Oncology Appoints Proven Biopharmaceutical Commercial Leader Isabel Kalofonos as Chief Commercial OfficerCGON · manilatimes.net · 13 Oct 2026
0 headlines in the last 90 days name James Mulay; 1 article from the last 14 days about the 1 company they traded most, at most three about any one of them.